Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
8,243 people get TEVA articles and Market Currents by email alert.
Get email alerts on TEVA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
Business Wire (Tue, 10:35AM)
-
-
-
-
-
-
-
-
-
-
Business Wire (May 8, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Teva's CEO Reviews Management Succession (Transcript)Tue, Jan 3, 2012
-
Teva CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 8, 2011 • 1 Comment
-
Teva Pharmaceutical Industries Limited Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010 • 1 Comment
-
Business Wire (Tue, 10:35AM)
-
at CNBC.com (May 9, 2013)
-
at CNBC.com (May 8, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 2, 2013)
-
at CNBC.com (Apr 26, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Apr 8, 2013)
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Limited (“Teva”) is a global pharmaceutical company that develops, produces and markets generic drugs in all major therapeutic categories. We are the leading generic drug company in the world – with the leading position in the U.S. (in terms of both value and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, December 18, 2012, 8:26 AM Teva (TEVA) halts the development of a proposed $300M distribution center in Northeast Philadelphia, saying that it "cannot elaborate further about plans for this property." Earlier this month, Teva said it's reassessing its international operations as part of a scheme to slash expenses by $1.5-2B over the next 3-5 years. Comment! [Healthcare]
- Monday, December 17, 2012, 6:17 AM Teva (TEVA) enters into a JV with South Korea's Handok Pharmaceuticals to sell the Israel company's drugs in the country, where the market is worth $14B and where healthcare spending is expected to hit 9% of GDP within three years. The move fits in with Teva's new strategy, which includes expanding its global presence and carrying out more business development. (PR) 1 Comment [Healthcare]
- Friday, December 14, 2012, 1:43 PM AstraZeneca (AZN +0.2%) says an Appeals Court has upheld the decision finding that the substance patent protecting Crestor is valid and enforceable. The defendants may seek a rehearing or review by the U.S. Supreme Court. Absent a reversal, none of the Abbreviated New Drug Applications filed may be approved by the FDA prior to expiration of the patent, which expires in 2016. The ruling covers rosuvastatin calcium, the active ingredient in Crestor. Comment! [Healthcare]
- Sunday, December 9, 2012, 2:27 AM The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous) 1 Comment [Healthcare, Top Stories]
- Friday, December 7, 2012, 4:41 AM The Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA). Comment! [Healthcare, Top Stories]
- Tuesday, December 4, 2012, 10:11 AM The patent cliff has been good for generic-drugs companies this year, with over 40 brand-name treatments with $35B of annual sales losing their IP protection. However, the sector faces its own patent cliff over the next couple of years, due to fewer drugs losing that protection. In response, the generic companies are specializing in treatments that are hard to make, selling their own branded medicines, or making big acquisitions. 1 Comment [Healthcare]
- Tuesday, December 4, 2012, 8:24 AM Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its NeuVax breast cancer treatment in Israel. While financial terms weren't disclosed, Teva will make significant royalty payments to Galena on future sales. Israel will be the location of at least four sites for Phase 3 trials of NeuVax. Comment! [On the Move, Healthcare]
- Friday, November 30, 2012, 7:09 AM Teva Pharmaceutical (TEVA) forecasts 2013 EPS of $4.85-$5.15 against Street expectations for $5.63. Total revenue is expected at $19.5B-$20.5B. Shares -5.5% premarket. (PR) 2 Comments [Healthcare, On the Move, Breaking News]
- Wednesday, November 28, 2012, 4:47 PM Rexahn Pharmaceuticals (RNN) says it intends to offer shares of its common stock and warrants in an underwritten public offering. The shares are being offered as units, with no amount given at present. Earlier today the company announced it would be receiving additional funding from Teva Pharmaceutical (TEVA) for the development of its potential tumor treatment RX-3117. Burrill and Maxim Group are acting as joint book-running mangers for the offering. Comment! [Healthcare]
- Wednesday, November 28, 2012, 12:53 PM Rexahn Pharmaceuticals (RNN +9%) trades higher after the company said that Teva Pharmaceutical (TEVA -0.6%) will provide an additional $750K in funding to the company. Pursuant to the terms of an earlier agreementl, TEVA will purchase RNN's common stock at 120% of its closing price on the last trading day preceding the closing. TEVA has also agreed to commit additional research funding for development of RX-3117, a potential treatment for solid tumors including colon, lung and pancreatic cancers, and will retain the right to file the Investigational New Drug application with the FDA. 2 Comments [Healthcare, On the Move]
- Tuesday, November 27, 2012, 3:00 PM Teva Pharmaceuticals (TEVA +0.9%) agrees to delay the introduction of generic versions of two Gilead (GILD -0.9%) HIV drugs, Truvada and Viread, until June 1 or until a judge rules on the patent fight between the two companies. GILD sued TEVA in 2008 and again in 2010, claiming its FDA applications to make HIV drugs infringed four of its patents. The complaints also listed the HIV drug Atripla, which wasn’t cited in today’s filing. Comment! [Healthcare, On the Move]
- Wednesday, November 21, 2012, 8:50 AM Teva (TEVA) is putting a freeze on the type of multi-billion dollar acquisitions that have spurred its growth, Chairman Phillip Frost indicates, unless something something "so compelling and so game-changing" crops up. Instead, "there is the opportunity for product acquisitions, for small company acquisitions, for technology acquisitions," Frost says. 1 Comment [Healthcare, M&A]
- Tuesday, November 20, 2012, 9:40 AM While multiple-sclerosis patients have waited years for pills to be developed to treat the debilitating disease, doctors are warning them to be wary. That's because drugs such as Novartis' (NVS) Gilenya and Sanofi's (SNY) Aubagio can have significant side-effects. All of which is positive for Teva (TEVA), whose Copaxone is injected rather than taken orally. 4 Comments [Healthcare]
- Tuesday, November 20, 2012, 9:20 AM While multiple-sclerosis patients have waited years for pills to be developed to treat the debilitating disease, doctors are warning them to be wary. That's because drugs such as Novartis' (NVS) Gilenya and Sanofi's (SNY) Aubagio can have significant side-effects. All of which is positive for Teva (TEVA), whose Copaxone is injected rather than taken orally. Comment! [Healthcare]
- Thursday, November 15, 2012, 8:28 AM Amarin (AMRN) +9% following a report that Teva (TEVA +0.7%) is leading the race to acquire the Irish biotech, which has a market cap of $1.6B, with AstraZeneca (AZN +0.4%) also in the hunt. Teva recently said it wasn't intending to make any major acquisitions, while it's also due to unveil a long-term overhaul in December. 3 Comments [Healthcare, On the Move, M&A]
- Monday, November 12, 2012, 1:14 PM E.U. regulators have approved Procter & Gamble's (PG +0.2%) acquisition of Teva's (TEVA +0.1%) over-the-counter business, saying it doesn't raise any competitive concerns. The agency had looked closely at the impact on markets for topical anti-rheumatics, analgesics and expectorants - particularly in the Baltic countries - but found no anti-trust risks. 4 Comments [Healthcare, Global & FX]
-
- View all 0 replies
-
Energysystems
Nice to see $AFL finally making me some $$. Now only one negative position in my portfolio($TEVA). - View all 1 replies
-
-
Retail Investor
$ESLT $CEL $TEVA $TARO - Shareholders discussion group to suggest proposals to maximize value -> http://bit.ly/RqPX2c - View all 0 replies
-
- View all 0 replies
-
Retail Investor
$TARO $TEVA $PRGO $VRX $VRX TARO to announce results . Questions shareholders should ask on prelim proxy ->http://bit.ly/VUtMHc - View all 0 replies
-
1980XLS-2.0
It appears the banksters that bought 26K Oct $42.50 call contracts (2 wks ago) in TEVA ( for about .15) , want their money back - View all 0 replies
-
1980XLS-2.0
TEVA. It appears the banksters that bought tens of thousands of Oct $42.50 calls a week or two ago, plan on not being denied. - View all 5 replies
-
1980XLS-2.0: I played it mostly with stock, got out yeasterday,with modest gains, thanks to filling position incrementally.Somebody lost big.
-
FortSumter: Turns out they were expecting an FDA approval which came yesterday.....oops, a little late. haha
-
- View all 0 replies
-
- View all 3 replies
-
-
-
FortSumter
TEVA Bought Oct $42.50 calls for $15. Pointed out by 1980 the 25k volume just for today at that strike. Gambling. - View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
Michael Bryant
Be careful buying Teva (TEVA) do to the Palestinian conflict. But I think this is just a short-term issue. http://yhoo.it/oa8IEj - View all 13 replies
-
-
Derek A. Barrett: Israel can defend itself 1000 times over, no need to worry.